A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1 in Combination With Paclitaxel in Solid Tumors

The Oncologist, 04/26/2012

CBT–1 is able to inhibit Pgp–mediated efflux from PBMCs and normal liver to a degree observed with Pgp inhibitors studied in earlier clinical trials. Combined with its ease of administration and lack of toxicity, the data showing inhibition of normal tissue Pgp support further studies with CBT–1 to evaluate its ability to modulate drug uptake in tumor tissue.

Print Article Summary Cat 2 CME Report